[1] Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development[J]. Nat Rev Genet, 2014, 15(1): 7-21
[2] Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 1015
[3] 胡旭东, 刘林, 李伟. 长非编码RNA的表达调控机制[J]. 中国生物化学与分子生物学报 (Hu X D, Liu L, Li W. Regulation mechanism of long non-coding RNA expression[J]. Chin J Biochem Mol Biol), 2021, 37(12): 1584-1591
[4] Xing C, Sun S G, Yue Z Q, et al. Role of lncRNA LUCAT1 in cancer[J]. Biomed Pharmacother, 2021, 134: 111158
[5] Necsulea A, Soumillon M, Warnefors M, et al. The evolution of lncRNA repertoires and expression patterns in tetrapods[J]. Nature, 2014, 505(7485): 635-640
[6] Lyu Q R, Zhang S, Zhang Z, et al. Functional knockout of long non-coding RNAs with genome editing[J]. Front Genet, 2023, 14: 1242129
[7] Xiao A, Wang Z, Hu Y, et al. Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish[J]. Nucleic Acids Res, 2013, 41(14): e141
[8] Wiedenheft B, Sternberg S H, Doudna J A. RNA-guided genetic silencing systems in bacteria and archaea[J]. Nature, 2012, 482(7385): 331-338
[9] Kondrateva E, Demchenko A, Lavrov A, et al. An overview of currently available molecular Cas-tools for precise genome modification[J]. Gene, 2021, 769: 145225
[10] Doudna J A, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9[J]. Science, 2014, 346(6213): 1258096
[11] 谈鎏, 叶邦策, 尹斌成. CRISPR/Cas系统中工程化gRNA技术的研究和应用[J]. 中国生物化学与分子生物学报 (Tan L, Ye B C, Yin B C. Research and application of the engineered gRNA technology in the CRISPR/Cas system[J]. Chin J Biochem Mol Biol), 2024, 40(8): 1078-1092
[12] Makarova K S, Haft D H, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems[J]. Nat Rev Microbiol, 2011, 9(6): 467-477
[13] Wang S W, Gao C, Zheng Y M, et al. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer[J]. Mol Cancer, 2022, 21(1): 57
[14] 巩琦凡, 郑晓飞, 付汉江. CRISPR基因编辑技术的发展及应用[J]. 中国生物化学与分子生物学报 (Gong Q F, Zheng X F, Fu H J. Development and application of CRISPR gene editing technology[J]. Chin J Biochem Mol Biol), 2023, 39(3): 332-340
[15] Yang C, Lei Y, Ren T, et al. The current situation and development prospect of whole-genome screening[J]. Int J Mol Sci, 2024, 25(1): 658
[16] 杨育宾, 黄卫人, 陈巍. CRISPR/Cas9系统在临床医学研究的应用与改进[J]. 中国生物化学与分子生物学报 (Yang Y B, Huang W R, Chen W. Application and improvement of the CRISPR/Cas9 system in clinical medical research[J]. Chin J Biochem Mol Biol), 2023, 39(1): 16-23
[17] Khan S H. Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application[J]. Mol Ther Nucleic Acids, 2019, 16: 326-334
[18] Kim J, Piao H L, Kim B J, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis[J]. Nat Genet, 2018, 50(12): 1705-1715
[19] Gasperini M, Findlay G M, Mckenna A, et al. CRISPR/Cas9-mediated scanning for regulatory elements required for HPRT1 expression via thousands of large, programmed genomic deletions[J]. Am J Hum Genet, 2017, 101(2): 192-205
[20] Zhang S, Chen Y, Dong K, et al. BESST: a novel LncRNA knockout strategy with less genome perturbance[J]. Nucleic Acids Res, 2023, 51(9): e49
[21] Li C, Sun C, Mahapatra K D, et al. Long noncoding RNA plasmacytoma variant translocation 1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity[J]. Br J Dermatol, 2024, 190(3): 415-426
[22] Yuan H, Ren Q, Du Y, et al. LncRNA miR663AHG represses the development of colon cancer in a miR663a-dependent manner[J]. Cell Death Discov, 2023, 9(1): 220
[23] Vishnubalaji R, Elango R, Alajez N M. LncRNA-based classification of triple negative breast cancer revealed inherent tumor heterogeneity and vulnerabilities[J]. Noncoding RNA, 2022, 8(4): 44
[24] Han J, Zhang J, Chen L, et al. Efficient in vivo deletion of a large imprinted lncRNA by CRISPR/Cas9[J]. RNA Biol, 2014, 11(7): 829-835
[25] Zhen S, Hua L, Liu Y H, et al. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer[J]. Oncotarget, 2017, 8(6): 9634-9646
[26] Jia Z, Wang Y, Sun X, et al. Effect of lncRNA XLOC_005950 knockout by CRISPR/Cas9 gene editing on energy metabolism and proliferation in osteosarcoma MG63 cells mediated by hsa-miR-542-3p[J]. Oncol Lett, 2021, 22(3): 669
[27] Yang J, Meng X, Pan J, et al. CRISPR/Cas9-mediated noncoding RNA editing in human cancers[J]. RNA Biol, 2018, 15(1): 35-43
[28] Doudna J A. The promise and challenge of therapeutic genome editing[J]. Nature, 2020, 578(7794): 229-236
[29] Zeng Y, Cullen B R. RNA interference in human cells is restricted to the cytoplasm[J]. RNA, 2002, 8(7): 855-860
[30] Roy Choudhury S, Heflin B, Taylor E, et al. CRISPR/dCas9-KRAB-mediated suppression of S100b restores p53-mediated apoptosis in melanoma cells[J]. Cells, 2023, 12(5): 730
[31] Strezoska Ž, Dickerson S M, Maksimova E, et al. CRISPR-mediated transcriptional activation with synthetic guide RNA[J]. J Biotechnol, 2020, 319: 25-35
[32] Pulido-Quetglas C, Johnson R. Designing libraries for pooled CRISPR functional screens of long noncoding RNAs[J]. Mamm Genome, 2022, 33(2): 312-327
[33] Hofman D A, Ruiz-Orera J, Yannuzzi I, et al. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma[J]. Mol Cell, 2024, 84(2): 261-76.e18
[34] 叶洲杰, 王心睿. CRISPR系统转化医学研究进展[J]. 生物技术通报 (Ye Z J, Wang X R. Research progress of CRISPR system in translational medicine[J]. Biotech Bulletin), 2020, 36(11): 188-197
[35] Hazan J M, Amador R, Ali-Nasser T, et al. Integration of transcription regulation and functional genomic data reveals lncRNA SNHG6’s role in hematopoietic differentiation and leukemia[J]. J Biomed Sci, 2024, 31(1): 27
[36] Ji Z, Song R, Regev A, et al. Many lncRNAs, 5′UTRs, and pseudogenes are translated and some are likely to express functional proteins[J]. Elife, 2015, 4: e08890
[37] Ingolia N T, Brar G A, Stern-Ginossar N, et al. Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes[J]. Cell Rep, 2014, 8(5): 1365-1379
[38] Bazzini A A, Johnstone T G, Christiano R, et al. Identification of small ORFs in vertebrates using ribosome footprinting and evolutionary conservation[J]. EMBO J, 2014, 33(9): 981-993
[39] Zheng C, Wei Y, Zhang P, et al. CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer[J]. J Clin Invest, 2023, 133(5): e159940
[40] Sandmann C L, Schulz J F, Ruiz-Orera J, et al. Evolutionary origins and interactomes of human, young microproteins and small peptides translated from short open reading frames[J]. Mol Cell, 2023, 83(6): 994-1011.e18
[41] Zhang Y. LncRNA-encoded peptides in cancer[J]. J Hematol Oncol, 2024, 17(1): 66
[42] Cheng R, Li F, Zhang M, et al. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers[J]. Cell Res, 2023, 33(1): 30-45
[43] Wu A H, Chen X L, Guo L Y, et al. Downregulation of lncRNA IGF2-AS-encoded peptide induces trophoblast-cycle arrest[J]. Reprod Biomed Online, 2021, 43(4): 598-606
[44] Pei H, Dai Y, Yu Y, et al. The tumorigenic effect of lncRNA AFAP1-AS1 is mediated by translated peptide ATMLP under the control of m(6) A methylation[J]. Adv Sci (Weinh), 2023, 10(13): e2300314
[45] Camarena M E, Theunissen P, Ruiz M, et al. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort[J]. Sci Adv, 2024, 10(28): eadn3628
[46] Shaath H, Vishnubalaji R, Elango R, et al. Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy[J]. Cell Death Discov, 2021, 7(1): 23
[47] Chang K W, Hung W W, Chou C H, et al. LncRNA MIR31HG drives oncogenicity by inhibiting the limb-bud and heart development gene (LBH) during oral carcinoma[J]. Int J Mol Sci, 2021, 22(16): 8383
[48] Shafaroudi A M, Sharifi-Zarchi A, Rahmani S, et al. Expression and function of C1orf132 long-noncoding RNA in breast cancer cell lines and tissues[J]. Int J Mol Sci, 2021, 22(13): 6768
[49] Carvelli A, Setti A, Desideri F, et al. A multifunctional locus controls motor neuron differentiation through short and long noncoding RNAs[J]. EMBO J, 2022, 41(13): e108918
[50] Ali T, Grote P. Beyond the RNA-dependent function of LncRNA genes[J]. Elife, 2020, 9: e60583
[51] Zhang X Z, Liu H, Chen S R. Mechanisms of long non-coding RNAs in cancers and their dynamic regulations[J]. Cancers (Basel), 2020, 12(5): 1245
[52] Farhadova S, Ghousein A, Charon F, et al. The long non-coding RNA Meg3 mediates imprinted gene expression during stem cell differentiation[J]. Nucleic Acids Res, 2024, 52(11): 6183-6200
[53] Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs[J]. Nat Rev Genet, 2020, 21(2): 102-117
[54] Labonté B, Abdallah K, Maussion G, et al. Regulation of impulsive and aggressive behaviours by a novel lncRNA[J]. Mol Psychiatry, 2021, 26(8): 3751-3764
[55] Guo R, Su Y, Zhang Q, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets[J]. J Transl Med, 2023, 21(1): 120
[56] Ci Y, Zhang Y, Zhang X. Methylated lncRNAs suppress apoptosis of gastric cancer stem cells via the lncRNA-miRNA/protein axis[J]. Cell Mol Biol Lett, 2024, 29(1): 51
[57] Wang Y, Liu Y, Zhang T, et al. LncCDCA3L inhibits cell proliferation via a novel RNA structure-based crosstalk with CDCA3 in hepatocellular carcinoma[J]. Liver Int, 2022, 42(6): 1432-1446
[58] Ma Z, Li S, Wang Y, et al. Upregulation of a novel LncRNA AC104958.2 stabilized by PCBP2 promotes proliferation and microvascular invasion in hepatocellular carcinoma[J]. Exp Cell Res, 2021, 407(1): 112791
[59] Duarte M J, Mascarenhas R S, Assis A F, et al. Autoimmune regulator act in synergism with thymocyte adhesion in the control of lncRNAs in medullary thymic epithelial cells[J]. Mol Immunol, 2021, 140: 127-135
[60] Shalem O, Sanjana N E, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells[J]. Science, 2014, 343(6166): 84-87
[61] Zhu S, Li W, Liu J, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library[J]. Nat Biotechnol, 2016, 34(12): 1279-1286
[62] Tous C, Muñoz-Redondo C, Gavilán A, et al. Delving into the role of lncRNAs in papillary thyroid cancer: upregulation of LINC00887 promotes cell proliferation, growth and invasion[J]. Int J Mol Sci, 2024, 25(3): 1587
[63] Haghighi N, Doosti A, Kiani J. Evaluation of apoptosis, cell proliferation and cell cycle progression by inactivation of the NEAT1 long noncoding RNA in a renal carcinoma cell line using CRISPR/Cas9[J]. Iran J Biotechnol, 2023, 21(1): e3180
[64] Tsung K, Liu K Q, Han J S, et al. CRISPRi screen of long non-coding RNAs identifies LINC03045 regulating glioblastoma invasion[J]. PLoS Genet, 2024, 20(6): e1011314
[65] Guardia T, Zhang Y, Thompson K N, et al. OBSCN restoration via OBSCN-AS1 long-noncoding RNA CRISPR-targeting suppresses metastasis in triple-negative breast cancer[J]. Proc Natl Acad Sci U S A, 2023, 120(11): e2215553120
[66] Fu L, Wang X, Yang Y, et al. Septin11 promotes hepatocellular carcinoma cell motility by activating RhoA to regulate cytoskeleton and cell adhesion[J]. Cell Death Dis, 2023, 14(4): 280
[67] Binnewies M, Roberts E W, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24(5): 541-550
[68] Galli F, Aguilera J V, Palermo B, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy[J]. J Exp Clin Cancer Res, 2020, 39(1): 89
[69] Liu J, Zhou W Y, Luo X J, et al. Long noncoding RNA regulating immune escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma[J]. Clin Transl Med, 2023, 13(9): e1410
[70] Martinez-Terroba E, Plasek-Hegde L M, Chiotakakos I, et al. Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment[J]. Sci Immunol, 2024, 9(96): eadh5462
[71] Nukala S B, Jousma J, Yan G, et al. Modulation of lncRNA links endothelial glycocalyx to vascular dysfunction of tyrosine kinase inhibitor[J]. Cardiovasc Res, 2023, 119(10): 1997-2013
[72] Weiss L M, Warwick T, Zehr S, et al. RUNX1 interacts with lncRNA SMANTIS to regulate monocytic cell functions[J]. Commun Biol, 2024, 7(1): 1131
[73] Shamloo S, Kloetgen A, Petroulia S, et al. Integrative CRISPR activation and small molecule inhibitor screening for lncRNA mediating BRAF inhibitor resistance in melanoma[J]. Biomedicines, 2023, 11(7): 2054
[74] Wen X, Han M, Hosoya M, et al. Identification of BRAF inhibitor resistance-associated lncRNAs using genome-scale CRISPR-Cas9 transcriptional activation screening[J]. Anticancer Res, 2024, 44(6): 2349-2358
[75] Grillone K, Ascrizzi S, Cremaschi P, et al. An unbiased lncRNAs dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma[J]. Blood, 2024, 144(16): 1705-1721
[76] Chan Y T, Wu J, Lu Y, et al. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC[J]. Mol Cancer, 2024, 23(1): 74
[77] Majumdar S, Chakraborty A, Das S, et al. Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1 activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes chemoresistance in hepatocellular carcinoma[J]. Cell Death Discov, 2024, 10(1): 274
[78] Long F, Li X, Pan J, et al. The role of lncRNA NEAT1 in human cancer chemoresistance[J]. Cancer Cell Int, 2024, 24(1): 236
[79] Matboli M, Kamel M M, Essawy N, et al. Identification of novel insulin resistance related ceRNA network in T2DM and its potential editing by CRISPR/Cas9[J]. Int J Mol Sci, 2021, 22(15): 8129
[80] Bi G, Liang J, Zhao M, et al. miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways[J]. Mol Ther Nucleic Acids, 2022, 28: 366-86
[81] Azadbakht N, Doosti A, Jami M S. CRISPR/Cas9-mediated LINC00511 knockout strategies, increased apoptosis of breast cancer cells via suppressing antiapoptotic genes[J]. Biol Proced Online, 2022, 24(1): 8
[82] Goyal A, Myacheva K, Gro M, et al. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes[J]. Nucleic Acids Res, 2017, 45(3): e12
[83] Zhang S, Shen J, Li D, et al. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing[J]. Theranostics, 2021, 11(2): 614-648
[84] Alkan F, Wenzel A, Anthon C, et al. CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters[J]. Genome Biol, 2018, 19(1): 177
[85] Guo C, Ma X, Gao F, et al. Off-target effects in CRISPR/Cas9 gene editing[J]. Front Bioeng Biotechnol, 2023, 11: 1143157
[86] Chen B, Deng S, Ge T, et al. Live cell imaging and proteomic profiling of endogenous NEAT1 lncRNA by CRISPR/Cas9-mediated knock-in[J]. Protein Cell, 2020, 11(9): 641-660
[87] Wang H, Nakamura M, Abbott T R, et al. CRISPR-mediated live imaging of genome editing and transcription[J]. Science, 2019, 365(6459): 1301-1305